Novakand Pharma AB (publ) (LARK) — Cash Flow-to-Debt Ratio
Novakand Pharma AB (publ) (LARK) has a Cash Flow-to-Debt Ratio of 0.42x as of June 2026, meaning its operating cash flow of Skr352.00K could theoretically repay 0% of its total liabilities (Skr846.00K) in one year. Check cash flow reinvestment rate of Novakand Pharma AB (publ) to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Novakand Pharma AB (publ) Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Novakand Pharma AB (publ) across 14 annual periods. Check Novakand Pharma AB (publ) earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Annual Cash Flow-to-Debt Ratio for Novakand Pharma AB (publ) (2012–2025)
Year-by-year debt coverage analysis for Novakand Pharma AB (publ). For the full cash flow conversion analysis, see how efficiently does Novakand Pharma AB (publ) generate cash.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -10.31x | Skr-12.78 Million | Skr1.24 Million | ▼ -48.1% |
| 2024 | -6.96x | Skr-29.95 Million | Skr4.30 Million | ▲ +5.3% |
| 2023 | -7.35x | Skr-30.56 Million | Skr4.16 Million | ▼ -169.1% |
| 2022 | -2.73x | Skr-16.67 Million | Skr6.10 Million | ▼ -198.1% |
| 2021 | 2.78x | Skr22.11 Million | Skr7.94 Million | ▲ +158.0% |
| 2020 | -4.80x | Skr-38.35 Million | Skr7.98 Million | ▼ -422.9% |
| 2019 | -0.92x | Skr-21.60 Million | Skr23.51 Million | ▼ -6018.6% |
| 2018 | 0.02x | Skr227.60K | Skr14.66 Million | ▲ +100.3% |
| 2017 | -5.86x | Skr-9.53 Million | Skr1.63 Million | ▲ +46.2% |
| 2016 | -10.88x | Skr-8.81 Million | Skr809.66K | ▼ -19.7% |
| 2015 | -9.09x | Skr-6.29 Million | Skr691.73K | ▼ -752.1% |
| 2014 | -1.07x | Skr-620.67K | Skr582.04K | ▲ +83.9% |
| 2013 | -6.64x | Skr-272.15K | Skr40.98K | ▼ -3426.4% |
| 2012 | 0.20x | Skr59.21K | Skr296.58K | — |